Nuclear receptor modulators

Abstract

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

1 - 2 . (canceled) 
     
     
         3 . A compound of Formula (Ia) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein
 G is CH; 
 J is CH; 
 W is C; 
 X is NR a , wherein R a  is —CH 3 , —CH 2 CH 3 , CH 2 CH(CH 3 ) 2 ; 
 Y is N; 
 A is C; 
 E is C; 
 V is CR 3 , wherein R 3  is H, Br, —CN, or —CF 3 ; 
 Z is CR 3  or N, wherein R 3  is H or CH 3 ; 
 L 1  is connected to W; 
 L 1  is —CH 2 — or —C(O)—; 
 L 2  is —CH 2 — or —C(O)—; 
 R 1  is —Cl or —CH 3 ; 
 R 2  is —Cl or —CH 3 ; 
 each R 3  is independently —Br, —Cl, —CN, —CH 3 , or —CF 3 ; and 
 R 4  is N(CH 2 CH 3 )—CH 2 CH 2 OH, —NH-optionally substituted cyclohexyl, —NH-optionally substituted oxetanyl, optionally substituted azetidinyl, optionally substituted 1,4-diazepanyl, optionally substituted 3-azabicyclo[3.1.0]hexanyl, optionally substituted morpholinyl, optionally substituted 2-oxa-6-azaspiro[3.3]heptanyl, optionally substituted 2-oxa-7-azaspiro[3.5]nonanyl, optionally substituted 2-oxa-8-azaspiro[4.5]decanyl, optionally substituted piperazinyl, optionally substituted piperidinyl, or optionally substituted pyrrolidinyl. 
 
     
     
         4 - 31 . (canceled) 
     
     
         32 . The compound according to  claim 3 , or a pharmaceutically acceptable salt thereof, wherein R 4  is selected from the group consisting of:
 1,4-diazepanyl optionally substituted with —CH 2 CH 2 OH;   azetidinyl optionally substituted with —OH, —CH 2 OH, —CH 2 CH 2 OH, —CH 2 OCH 3 , —CH 2 CH 2 OCH 3 , —N(CH 3 ) 2 , or pyrrolidinyl;   3-azabicyclo[3.1.0]hexanyl optionally substituted with —COOH or —CO 2 CH 3 CH 3 ;   morpholinyl optionally substituted with ═O;   piperazinyl optionally substituted with —F, —CH 3 , —CH(CH 3 ) 2 , —CH 2 CF 3 , —COOH, —CH 2 — cyclopropyl, —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —CH 2 CH(OH)CH 3 , —CH 2 CH(F)CH 3 , cyclobutanecarboxylic acid, or oxetanyl;   piperidinyl optionally substituted with —CH 3 , —CH 2 COOH, —CH 2 OH, —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —C(CH 3 ) 2 CH 2 OH, —C(CH 3 ) 2 OH, —C(CH 3 ) 2 CH 2 OH, —CH(OH)CH 3 , —CH 2 CH(OH)CH 3 , —CH 2 C(CH 3 ) 2 OH, —CH 2 OCH 3 , —COOH, —OH, —OCH 3 , —N(CH 3 ) 2 , or oxetanyl; and   pyrrolidinyl optionally substituted with —CH 2 CH 2 OH, —CH 2 OCH 3 ,—CONHCH 3 , —OH, or —OCH 3 .   
     
     
         33 . The compound according to  claim 3 , wherein the compound is selected from the group consisting of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof.